You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Patent: 5,447,725


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,447,725
Title: Methods for aiding periodontal tissue regeneration
Abstract:Methods for aiding periodontal tissue regeneration with compositions containing bioresorbable polymers, leachable solvents, and bioavailable drug actives. The compositions useful for these methods are characterized by becoming harder upon contact with the periodontal tissue such that the composition is effective for aiding tissue regeneration and by releasing a therapeutically-effective amount of drug active agent.
Inventor(s): Damani; Nalinkant C. (Cincinnati, OH), Mohl; Douglas C. (Fairfield, OH), Singer, Jr.; Robert E. (Fairfield, OH)
Assignee: The Procter & Gamble Company (Cincinnati, OH)
Application Number:08/076,304
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 5,447,725

Introduction

United States Patent 5,447,725, issued on September 5, 1995, is a patent that has been part of the intellectual property landscape for nearly three decades. To conduct a comprehensive and critical analysis of its claims and the surrounding patent landscape, we need to delve into several key areas, including the patent's subject matter, the process of patentability assessment, and the evolving legal and technological context.

Understanding the Patent

Subject Matter

To begin, it is crucial to understand the subject matter of the patent. Patent 5,447,725 would typically fall under one of the categories defined by the Patent Act, such as a process, machine, manufacture, or composition of matter, or an improvement thereof[2].

Claims Analysis

The claims of a patent are its most critical component, as they define the scope of the invention. A thorough analysis involves examining each claim for novelty, nonobviousness, and enablement. Here, we must determine if the claimed invention was new and not obvious at the time of filing, and if the patent provides sufficient information to enable a person skilled in the art to make and use the invention[2].

Patentability Assessment

Novelty Requirement

The novelty requirement is fundamental to patentability. The invention must not have been patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention[2].

Nonobviousness Requirement

Even if the invention is novel, it must also be nonobvious. This means that the invention must be significantly different from existing prior art and not an obvious combination of known elements[2].

Enablement Requirement

The enablement requirement ensures that the patent provides enough detail so that a person skilled in the art can make and use the invention without undue experimentation. Recent guidelines from the USPTO emphasize the importance of consistent analysis of this requirement[4].

Prior Art Search

Tools and Resources

Conducting a thorough prior art search is essential for assessing patentability. Resources such as the USPTO's Patent Public Search tool, Global Dossier, and the Common Citation Document (CCD) application are invaluable. These tools provide access to prior art from various international patent offices and help in identifying related applications and citations[1].

Challenges in Scientific Industries

In scientific industries, such as biotechnology and chemistry, the complexity of the technology and the ever-changing nature of the field pose significant challenges. For example, RNA innovations involve complex aspects like nanoparticle delivery, ligands, and chemical modifications, which require a comprehensive search strategy to identify all relevant prior art[3].

Intellectual Property Entanglements

Freedom to Operate

Intellectual property entanglements can significantly impact the patentability and commercialization of an invention. Companies must conduct freedom-to-operate searches to ensure that their innovation does not infringe on existing patents. This is particularly critical in highly regulated industries where cross-licensing agreements, research collaborations, and mergers and acquisitions can create complex IP landscapes[3].

Legal and Technological Context

The Leahy-Smith America Invents Act (AIA)

The AIA, enacted in 2011, introduced significant changes to U.S. patent law, including the creation of the Patent Trial and Appeal Board (PTAB). PTAB provides a faster and less expensive way to challenge patent validity compared to federal court litigation, which can be advantageous for entities accused of patent infringement[2].

Use of AI Tools

Recent guidance from the USPTO on the use of AI tools in patent drafting highlights the need for practitioners to verify the accuracy of factual assertions and ensure that AI contributions do not introduce inaccurate statements or omit material information[5].

International Patent Landscape

Global Patent Databases

To fully understand the patent landscape, it is essential to search international patent databases. Resources like the European Patent Office's esp@cenet, the Japan Patent Office's database, and the World Intellectual Property Organization's PATENTSCOPE provide access to global prior art and help in identifying potential IP entanglements[1].

Keeping Up with the Evolving Landscape

Continuous Monitoring

The patent landscape is constantly evolving, with new patents being filed daily. Innovators must continuously monitor this landscape to stay ahead. For instance, in the RNA innovation field, over 10,000 patents have been issued in the last decade, making it crucial to have effective search strategies and tools to navigate this complex documentation[3].

Case Study: Enbrel

The case of Enbrel, a blockbuster drug for treating rheumatoid arthritis, illustrates the complexities of IP entanglements. The original patent on Enbrel was co-owned by Immunex and Wyeth Pharmaceuticals, leading to a complex legal battle over patent rights. This case highlights the importance of managing IP entanglements to avoid legal disputes and ensure freedom to operate[3].

Key Takeaways

  • Thorough Prior Art Search: Conducting a comprehensive prior art search using various tools and resources is crucial for assessing patentability.
  • Intellectual Property Entanglements: Identifying and managing IP entanglements is vital to ensure freedom to operate and avoid legal disputes.
  • Legal and Technological Context: Understanding the legal framework, such as the AIA, and the role of AI tools in patent drafting is essential for navigating the patent landscape.
  • Continuous Monitoring: The patent landscape is dynamic, and continuous monitoring is necessary to stay ahead of new developments.
  • Global Considerations: Searching international patent databases is critical for a complete understanding of the global patent landscape.

FAQs

Q: What is the significance of the Leahy-Smith America Invents Act (AIA) in patent law?

A: The AIA is the most significant patent statute enacted in over 50 years, introducing the Patent Trial and Appeal Board (PTAB) and new administrative challenges to patent validity, aimed at improving patent quality and reducing litigation by "patent trolls"[2].

Q: How do intellectual property entanglements impact patentability?

A: IP entanglements can restrict a company's IP rights and freedom to operate, particularly in highly regulated industries, and must be identified and managed to avoid legal disputes and ensure commercialization[3].

Q: What are the key requirements for patentability?

A: The key requirements include novelty, nonobviousness, and enablement. The invention must be new, not obvious, and provide sufficient detail for a person skilled in the art to make and use it[2].

Q: How can AI tools be used in patent drafting?

A: AI tools can assist in drafting portions of the specification and claims, but practitioners must verify the accuracy of factual assertions and ensure that AI contributions do not introduce inaccuracies or omit material information[5].

Q: Why is continuous monitoring of the patent landscape important?

A: Continuous monitoring is essential because the patent landscape is constantly evolving, with new patents being filed daily, which can impact the novelty and nonobviousness of an invention and affect commercialization strategies[3].

Sources

  1. USPTO: Search for patents - USPTO
  2. Congressional Research Service: The Patent Trial and Appeal Board and Inter Partes Review
  3. CAS.org: Navigating patentability assessments in scientific industries
  4. FederalRegister.gov: Guidelines for Assessing Enablement in Utility Applications
  5. BIPC: U.S. Patent Office Issues Additional Guidance on Use of AI Tools

More… ↓

⤷  Subscribe

Details for Patent 5,447,725

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Grifols Biologicals Llc PROFILNINE, PROFILNINE HP, PROFILNINE HT, PROFILNINE SD factor ix complex For Injection 102476 July 20, 1981 5,447,725 2040-01-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.